Evaluation of FGD3 Expression in Advanced Prostate Cancer

Background/Objectives: Prostate cancer (PCa) is a leading health issue among men, with its impact varying significantly from one individual to another. The Faciogenital Dysplasia 3 (FGD3) has been described as a strong independent prognostic marker in breast cancer. The aim of our study was to investigate the possible impact of FGD3 expression on PCa progression and aggressiveness, as well as its correlation with clinical outcomes. Methods: Expression of FGD3 has been evaluated by immunohistochemical methods. The study cohort was enriched for cases with poorer prognosis and locally advanced disease, with complete clinicopathological data available, including age, Grade Group (ISUP), pathological T stage (pT), nodal status (pN), Gleason score, prostate-specific antigen (PSA) levels, and TNM stage. Results: Analysis of FGD3 immunoexpression revealed significant differences between control prostate tissue, primary prostate cancer tissue, and lymph node metastases. Pairwise comparisons showed significantly lower FGD3 expression in prostate cancer tissues compared with control tissues (p = 0.0483). Moreover, FGD3 expression was significantly reduced in lymph node metastases compared with both control tissues (p < 0.0001) and primary prostate cancer tissues (p < 0.0001). Conclusions: FGD3 was determined for the first time in patients with advanced prostate cancer. Our findings showed that reduced FGD3 expression has adverse prognostic significance in PCa. Further investigation is needed to confirm its possible use in daily clinical practice.